Kymera Investor Day Presentation Deck

Mechanistic Modeling Allowed Kymera to Accurately Predict Human PK and PD from Preclinical Dog Data for Clinical Candidate KT-474 Mechanistic PK/PD Modeling Describes the MoA of TPD Drug IV, SC, PO Ka PD (R) Target Protein 84 Tissue Keo EC50 Cp Ct d.R Plasma Kel PK Elimination PD dt Ksyn Kdeg = ksyn — kdeg (1 + EmaxxCt BCSo+Ct R KYMERA ©2021 KYMERA THERAPEUTICS, INC. % IRAK4 100 80 60 40 20 100 80 60 40 20 Preclinical Species Models for PK/PD KT-474 in Dog Ⓡ 0.3 mg/kg D2001 0 48 96 144 192 240 288 10 mg/kg D5001 0 0 48 96 144 192 240 288 0 0.3 mg/kg 0.3 mg/kg D2501 as.factor(dose) 1 mg/kg 10 mg/kg 3 mg/kg 1 mg/kg D3001 48 96 144 192 240 288 10 mg/kg D5501 48 96 144 192 240 288 • 0 48 96 144 192 240 288 Time (h) ● 3 mg/kg D4001 1 mg/kg D3501 0 48 96 144 192 240 288 0 48 96 144 192 240 288 0 48 96 144 192 240 288 KYMERA R&D DAY - December 16th, 2021 3 mg/kg D4501 Predicted % IRAK4 Reduction from Baseline Model Predicts Human PK/PD 0 20 40 60 80 85 K 100 0.01 DC85= 3 ng/mL 0.1 10 Plasma KT-474 Ctrough (ng/mL) 1 Dog Human 100 PAGE 95

View entire presentation